Payment overview · 2025
General Payments
$768.95
32 reported records · 13 companies
Healthcare provider profile · identity verified
Peter Edward Allotey, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MACON, GA · NPI 1164482808
Verified facts
What the public records show
CMS Open Payments records show Peter Edward Allotey, MD received $768.95 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $259.07 | 33.7% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.58 | 14.0% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $67.79 | 8.8% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $54.14 | 7.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.50 | 6.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.60 | 6.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.17 | 5.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.21 | 3.9% | 2 | 2025 |
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $29.58 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.97 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.37 | 2.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.15 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.82 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $768.95 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.86 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $111.81 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $107.58 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $80.83 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $67.79 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.50 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.60 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.17 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.48 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.21 | 2 | 2025 |
Source payment records
|
|||||
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 89 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 46 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
94 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
182 | 182 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
202 | 164 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1299 | 394 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1084 | 351 |
| Furosemide | Furosemide | 627 | 184 |
| Losartan Potassium | Losartan Potassium | 587 | 179 |
| Metformin Hcl | Metformin Hcl | 573 | 171 |
| Carvedilol | Carvedilol | 480 | 153 |
| Hydrochlorothiazide | Hydrochlorothiazide | 436 | 136 |
| Pravastatin Sodium | Pravastatin Sodium | 421 | 123 |
| Omeprazole | Omeprazole | 418 | 128 |
| Hydralazine Hcl | Hydralazine Hcl | 416 | 138 |
| Pantoprazole Sodium | Pantoprazole Sodium | 383 | 110 |
| Gabapentin | Gabapentin | 382 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 347 | 113 |
| Metoprolol Tartrate | Metoprolol Tartrate | 317 | 86 |
| Allopurinol | Allopurinol | 315 | 91 |
| Famotidine | Famotidine | 312 | 84 |
| Ezetimibe | Ezetimibe | 304 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 302 | 97 |
| Potassium Chloride | Potassium Chloride | 298 | 95 |
| Glimepiride | Glimepiride | 265 | 84 |
| Lisinopril | Lisinopril | 254 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 242 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 74 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 202 | 164 |
| Alprazolam | Alprazolam | 187 | 36 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 182 | 182 |
| Montelukast Sodium | Montelukast Sodium | 163 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 162 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 155 | 48 |
| Simvastatin | Simvastatin | 155 | 41 |
| Nifedipine Er | Nifedipine | 154 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 153 | 34 |
| Trazodone Hcl | Trazodone Hcl | 150 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 51 |
| Eliquis | Apixaban | 142 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 59 |
| Spironolactone | Spironolactone | 135 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 131 | 45 |
| Chlorthalidone | Chlorthalidone | 129 | 47 |
| Januvia | Sitagliptin Phosphate | 127 | 33 |
| Tramadol Hcl | Tramadol Hcl | 120 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 107 | 41 |
| Ibuprofen | Ibuprofen | 104 | 48 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 104 | 52 |
| Alendronate Sodium | Alendronate Sodium | 99 | 35 |
| Glipizide Er | Glipizide | 98 | 31 |
| Meloxicam | Meloxicam | 96 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 53 |
| Linzess | Linaclotide | 94 | 35 |
| Farxiga | Dapagliflozin Propanediol | 89 | 20 |
| Mounjaro | Tirzepatide | 89 | 18 |
| Fluconazole | Fluconazole | 87 | 67 |
| Ozempic | Semaglutide | 86 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 37 |
| Meclizine Hcl | Meclizine Hcl | 81 | 32 |
| Azithromycin | Azithromycin | 79 | 73 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 19 |
| Donepezil Hcl | Donepezil Hcl | 78 | 25 |
| Clonidine Hcl | Clonidine Hcl | 76 | 24 |
| Jardiance | Empagliflozin | 76 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 73 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 26 |
| Tradjenta | Linagliptin | 72 | 13 |
| Telmisartan | Telmisartan | 71 | 21 |
| Myrbetriq | Mirabegron | 66 | 18 |
| Indapamide | Indapamide | 60 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 22 |
| Atenolol | Atenolol | 58 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 16 |
| Cefuroxime | Cefuroxime Axetil | 55 | 50 |
| Sucralfate | Sucralfate | 54 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 52 | 28 |
| Finasteride | Finasteride | 51 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 14 |
| Buspirone Hcl | Buspirone Hcl | 46 | 20 |
| Rybelsus | Semaglutide | 46 | 11 |
| Topiramate | Topiramate | 45 | 11 |
| Entresto | Sacubitril/Valsartan | 44 | 11 |
| Levetiracetam | Levetiracetam | 44 | 14 |
| Memantine Hcl | Memantine Hcl | 44 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 18 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 15 |
| Mupirocin | Mupirocin | 40 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 35 |
| Ketoconazole | Ketoconazole | 39 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | 13 |
| Irbesartan | Irbesartan | 36 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Colchicine | Colchicine | 31 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 31 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | 12 |
| Nitroglycerin | Nitroglycerin | 30 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 26 |
| Glipizide | Glipizide | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 22 | 21 |
| Brilinta | Ticagrelor | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Mitigare | Colchicine | 20 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 13 |
| Folic Acid | Folic Acid | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Desloratadine | Desloratadine | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Terconazole | Terconazole | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $768.95 · 32 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, FARXIGA, IBSRELA, JARDIANCE, Kerendia, LINZESS, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, OTEZLA, Ozempic, REPATHA, Rybelsus, TOLMETIN SODIUM, TRELEGY ELLIPTA, TZIELD, Veozah | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error